Abstract:Chemokine receptor CCR2 is a member of the seven-transmembrane G-protein-coupled receptor superfamily, and is predominantly expressed on monocytes and macrophages. The interaction of the chemokine CCL2 with the CCR2 plays an important role in the recruitment of monocytes, natural killer cells, dendritic cells and T-lymphocytes. Recent studies have linked the CCL2/CCR2 axis to various inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, atherosclerosis, diabetes and even cancer. Thus, small molecule antagonists which can block the binding of CCR2 and CCL2 represent new therapeutic interventions of the inflammation-related diseases. By comprehensively analyzing the structures of the literature-reported potent CCR2 antagonists, we concluded a pharmacophore model for CCR2 inhibition, including a basic amino center, a hydrophobic aromatic ring on the right-hand side, and an amide group which serves as a hydrogen bond acceptor and a hydrogen bond donor. Then we performed the lead deconstruction and pharmacophore model-based privileged fragment reassembly strategy to discover new scaffold small molecule CCR2 inhibitors. The lead-like privileged scaffolds of alpha-alkyl-gamma-aminobutanamide and glycinamide were selected to combine with novel aromatic moiety and amide portion, delivering 3 classes of new structure CCR2 inhibitors. Total 11 compounds were designed and synthesized via a facile convergent synthetic procedure. The CCR2 antagonism activity evaluation revealed that N-(3-aminocyclopentane-carboxamido) methyl) benzamide was an active scaffold (exemplified by 1a, IC50= 25 nmol/L). The preliminary structure-activity relationship study indicated that the basic amino group and the lipophilic aliphatic moiety and small size aromatic group are important for the interaction with CCR2 protein. The replacement of the basic amino group with an amide would lead to the significant loss of the activity. This work provides a promising new structure CCR2 inhibitor and useful SAR conclusions which will promote the further development of CCR2 inhibitor into drug candidate.

Study of Molecular Design for Antagonisting C5a Anaphylatoxin

Molecular design for antagonisting C5a anaphyl atoxin and the activity examination of the peptide

Biomolecular Interactions Between Sense Peptides and Its Antisense Peptides of the Human Anaphyiatoxin C5a

Cloning and Expression of the Antisense Cdna of the Human C5a Anaphylatoxin in E.coli and Antagonism

Chimeric Protein Probes for C5a Receptors Through Fusion of the Anaphylatoxin C5a Core Region with a Small-Molecule Antagonist

Identification of Conformational Core Epitope Lys(68) in C5a Based on the 3-D Modeling Complex C5a and Its Functional Antibody F20

Molecular Design,pharmacology and Toxicology Optimization of Antimicrobial Peptide from Hydrophis Cyanocinctus,hc-Cath

Functional Identification of the Stable Transfection C5ar Cell Line Molt-4

Chemical Synthesis and Racemic Crystallization of Rat C5a-desArg

Computational Studies of the Binding Modes of Ccr1 Antagonists

Pharmacophore Model-based Design and Synthesis of New Structure Small Molecule CCR2 Inhibitors

Revealing the signaling of complement receptors C3aR and C5aR1 by anaphylatoxins

Illumination of the complement receptors C3aR and C5aR signaling by anaphylatoxins

The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses.

Improving the Anti-Toxin Abilities of the CMG2-Fc Fusion Protein with the Aid of Computational Design

Studies On The Interactions Between Lactam Analogs And The N-Terminal Extracellular Tail Of Cc Chemnokine Receptor 4 By Cze

C5L2 is no longer an orphan receptor——progress and prospect

Structure-based drug design using GPCR homology modeling: toward the discovery of novel selective CysLT2 antagonists.

Larrick, James W. et al. “Characterization of Murine Monoclonal Antibodies that Recognize Neutralizing Epitopes on Human C5a'

Epitopes Prediction for Microcystin-Lr by Molecular Docking

Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727